ERYTech: Stronger penetration of Oncaspar in the US. Positive read-across for GRASPA

BUY, Fair Value EUR42 (+45%)
News published on October Friday 30, 2015
Share on

Yesterday, Baxalta released its Q3 15 results, which now integrate the recently-completed Oncaspar (pegylated form of asparaginase) acquisition. Interestingly, Oncaspar sales are now “approaching an annual run rate of USD200m”. We think this is due to a deeper penetration of the different forms of asparaginases in the US, notably following the accumulation of studies demonstrating the superiority of asparaginase-based regimens in adults with Phi- ALL. This is quite positive for Erytech as: 1/ it shows that the penetration of the different forms of this therapeutic enzyme should increase in the coming years, and 2/ by expanding its reach to the frontline setting, GRASPA would benefit from these upward trends.


For more information, please contact marketing@bryangarnier.com  

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities